Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage
| Autor: | Masamitsu Shimazawa, Hideaki Hara, Kazuhiro Tsuruma, Yuko Nonaka, Toru Iwama, Shinichi Yoshimura |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
medicine.medical_specialty Ischemia Tetrazoles Brain damage Brain Ischemia Brain ischemia Mice chemistry.chemical_compound medicine.artery Internal medicine Animals Medicine Stroke Cerebral Hemorrhage Evans Blue business.industry Cerebral infarction General Neuroscience Brain Infarction Middle Cerebral Artery Cerebral Infarction medicine.disease Cilostazol Disease Models Animal Neuroprotective Agents Treatment Outcome chemistry Anesthesia Middle cerebral artery Cardiology Indicators and Reagents medicine.symptom business medicine.drug |
| Zdroj: | Neuroscience Letters. 452:156-161 |
| ISSN: | 0304-3940 |
| Popis: | Cilostazol, an antiplatelet drug used to treat intermittent claudication, has been reported to offer neuroprotection and endothelial protection in animals with ischemic brain injury. Here, we evaluated the protection afforded by cilostazol against ischemic brain injury and hemorrhagic transformation. Mice subjected to a 2-h filamental middle cerebral artery (MCA) occlusion were treated with cilostazol (10mg/kg, intraperitoneally just after the occlusion) or with vehicle. Histological outcomes (infarct volume and hemorrhagic transformation) and Evans blue extravasation were assessed after reperfusion. Mean infarct volume, hemorrhagic transformation, and Evans blue extravasation were all significantly reduced in the cilostazol-treated group. Thus, cilostazol protected against ischemic brain injury and hemorrhagic transformation in mice subjected to transient focal cerebral ischemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect